Breaking News, Collaborations & Alliances

vTv Therapeutics, Reneo Pharmaceuticals Enter Agreement

The licensing agreement focuses on the PPAR-delta program

vTv Therapeutics has entered into a global licensing agreement with Reneo Pharmaceuticals.    The agreement grants Reneo Pharmaceuticals exclusive worldwide rights to research, develop and commercialize vTv Therapeutics’ selective peroxisome proliferator-activated receptor delta (PPAR-delta) program. Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters